-
2
-
-
40949132576
-
Health supervision for children with neurofibromatosis.
-
Hersh JH. Health supervision for children with neurofibromatosis. Pediatrics 2008: 121 (3): 633-642.
-
(2008)
Pediatrics
, vol.121
, Issue.3
, pp. 633-642
-
-
Hersh, J.H.1
-
3
-
-
0025186923
-
Neurofibromatosis-1: a maximum likelihood estimation of mutation rate.
-
Clementi M, Barbujani G, Turolla L, Tenconi R. Neurofibromatosis-1: a maximum likelihood estimation of mutation rate. Hum Genet 1990: 84 (2): 116-118.
-
(1990)
Hum Genet
, vol.84
, Issue.2
, pp. 116-118
-
-
Clementi, M.1
Barbujani, G.2
Turolla, L.3
Tenconi, R.4
-
4
-
-
0030957310
-
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.
-
Gutmann DH, Aylsworth A, Carey JC et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997: 278 (1): 51-57.
-
(1997)
JAMA
, vol.278
, Issue.1
, pp. 51-57
-
-
Gutmann, D.H.1
Aylsworth, A.2
Carey, J.C.3
-
5
-
-
0034094731
-
Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.
-
DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000: 105(3 Pt 1): 608-614.
-
(2000)
Pediatrics
, vol.105
, Issue.3 PART 1
, pp. 608-614
-
-
DeBella, K.1
Szudek, J.2
Friedman, J.M.3
-
6
-
-
0034081412
-
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.
-
Messiaen LM, Callens T, Mortier G et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000: 15 (6): 541-555.
-
(2000)
Hum Mutat
, vol.15
, Issue.6
, pp. 541-555
-
-
Messiaen, L.M.1
Callens, T.2
Mortier, G.3
-
7
-
-
84870505201
-
-
University of Alabama at Birmingham. Medical Genetics Laboratory, from. Accessed on May 1, 2011.
-
University of Alabama at Birmingham. Medical Genetics Laboratory 2008, from http://medicine.uab.edu/genetics/82633/medgenomics/. Accessed on May 1, 2011.
-
(2008)
-
-
-
8
-
-
0027395630
-
National neurofibromatosis foundation international database.
-
Friedman JM, Birch P, Greene C. National neurofibromatosis foundation international database. Am J Med Genet 1993: 45 (1): 88-91.
-
(1993)
Am J Med Genet
, vol.45
, Issue.1
, pp. 88-91
-
-
Friedman, J.M.1
Birch, P.2
Greene, C.3
-
9
-
-
34147172816
-
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
-
Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007: 61 (3): 189-198.
-
(2007)
Ann Neurol
, vol.61
, Issue.3
, pp. 189-198
-
-
Listernick, R.1
Ferner, R.E.2
Liu, G.T.3
Gutmann, D.H.4
-
10
-
-
17644388078
-
Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)?
-
Alwan S, Tredwell SJ, Friedman JM. Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)? Clin Genet 2005: 67 (5): 378-390.
-
(2005)
Clin Genet
, vol.67
, Issue.5
, pp. 378-390
-
-
Alwan, S.1
Tredwell, S.J.2
Friedman, J.M.3
-
11
-
-
84870551504
-
-
British Columbia Ministry of Health. Medical Services Commission Payment Schedule, from. Accessed on May 1, 2011
-
British Columbia Ministry of Health. Medical Services Commission Payment Schedule 2011, from http://www.health.gov.bc.ca/msp/infoprac/physbilling/payschedule/index.html. Accessed on May 1, 2011.
-
(2011)
-
-
-
12
-
-
66549119634
-
Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children.
-
Regier DA, Friedman JM, Makela N, Ryan M, Marra CA. Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children. Clin Genet 2009: 75 (6): 514-521.
-
(2009)
Clin Genet
, vol.75
, Issue.6
, pp. 514-521
-
-
Regier, D.A.1
Friedman, J.M.2
Makela, N.3
Ryan, M.4
Marra, C.A.5
-
13
-
-
70349498475
-
Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options.
-
Elefteriou F, Kolanczyk M, Schindeler A et al. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 2009: 149A (10): 2327-2338.
-
(2009)
Am J Med Genet A
, vol.149 A
, Issue.10
, pp. 2327-2338
-
-
Elefteriou, F.1
Kolanczyk, M.2
Schindeler, A.3
|